Physician profile
Bobby C Pankey
NPI 1235183617
$1,534.44
in general payments reported to CMS, 2019-2025
10 companies · $94.11 in 2025
The $94.11 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $94.94 · 2021: $215 · 2022: $86.41 · 2023: $476 · 2024: $376 · 2025: $94.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $656.71 | 2019-2025 | Total30, Clareon, Precision7 |
| Mallinckrodt Hospital Products INC. | $369.16 | 2023-2024 | Acthar |
| Johnson & Johnson Vision Care, INC. | $190.97 | 2020-2025 | Acuvue |
| Optos, INC. | $126.01 | 2019 | |
| Dompe US, INC. | $53.05 | 2024 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $36.31 | 2022-2025 | Cirrus Hd-Oct |
| Bausch & Lomb Americas INC. | $35.48 | 2022-2023 | Vyzulta |
| Tarsus Pharmaceuticals, INC. | $33.29 | 2024 | Xdemvy |
| Coopervision INC. | $17.36 | 2023 | Biofinity Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Pankey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.